A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease

Stopped The trial was discontinued due to a lower than anticipated recruitment rate. The decision has not been made due to any safety reasons.

Conditions

• Chronic Kidney Diseases

Interventions

• DRUG: Visipaque
• DRUG: Placebos

Sponsor

GE Healthcare

Collaborators

• [object Object]